Multi-target approach to metastatic adrenal cell carcinoma

Research output: Contribution to journalArticle

Abstract

Adrenal cell carcinoma is a rare tumor and more than 70% of patients present with advanced stages. Adrenal cell carcinoma is an aggressive tumor with a poor prognosis. Surgical intervention is the gold standard treatment and mitotane is the only drug approved for the treatment of adrenal cell carcinoma. Until recently in 2012, the etoposide, doxorubicin, cisplatin plus mitotane are approved as first-line therapy based on response rate and progression-free survival. This case illustrates a case of advanced adrenal cell carcinoma in a young girl who presented with huge adrenal mass with inferior vena cava thrombosis and pulmonary embolism. Multi-approach of therapy was used to control the tumor size and metastasis. Therefore, it may prolong her survival rate for up to 5 years and 4 months.

Original languageEnglish
Pages (from-to)671-673
Number of pages3
JournalArchives of Iranian Medicine
Volume19
Issue number9
Publication statusPublished - 1 Sep 2016

Fingerprint

Mitotane
Carcinoma
Neoplasms
Inferior Vena Cava
Etoposide
Therapeutics
Pulmonary Embolism
Doxorubicin
Cisplatin
Disease-Free Survival
Thrombosis
Survival Rate
Neoplasm Metastasis
Pharmaceutical Preparations

Keywords

  • Advanced adrenal cell carcinoma
  • Mitotane
  • Radiofrequency ablation
  • Sorafenib
  • Surgical resection

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Multi-target approach to metastatic adrenal cell carcinoma. / A. Wahab @ A. Rahman, Norasyikin; Zainudin, Suehazlyn; Abaziz, Aini; Mustafa, Norlaila; Sukor, Norlela; Kamaruddin, Nor Azmi.

In: Archives of Iranian Medicine, Vol. 19, No. 9, 01.09.2016, p. 671-673.

Research output: Contribution to journalArticle

@article{0d1a87c352af43c2868d8fbf342ba3cd,
title = "Multi-target approach to metastatic adrenal cell carcinoma",
abstract = "Adrenal cell carcinoma is a rare tumor and more than 70{\%} of patients present with advanced stages. Adrenal cell carcinoma is an aggressive tumor with a poor prognosis. Surgical intervention is the gold standard treatment and mitotane is the only drug approved for the treatment of adrenal cell carcinoma. Until recently in 2012, the etoposide, doxorubicin, cisplatin plus mitotane are approved as first-line therapy based on response rate and progression-free survival. This case illustrates a case of advanced adrenal cell carcinoma in a young girl who presented with huge adrenal mass with inferior vena cava thrombosis and pulmonary embolism. Multi-approach of therapy was used to control the tumor size and metastasis. Therefore, it may prolong her survival rate for up to 5 years and 4 months.",
keywords = "Advanced adrenal cell carcinoma, Mitotane, Radiofrequency ablation, Sorafenib, Surgical resection",
author = "{A. Wahab @ A. Rahman}, Norasyikin and Suehazlyn Zainudin and Aini Abaziz and Norlaila Mustafa and Norlela Sukor and Kamaruddin, {Nor Azmi}",
year = "2016",
month = "9",
day = "1",
language = "English",
volume = "19",
pages = "671--673",
journal = "Archives of Iranian Medicine",
issn = "1029-2977",
publisher = "Academy of Medical Sciences of I.R. Iran",
number = "9",

}

TY - JOUR

T1 - Multi-target approach to metastatic adrenal cell carcinoma

AU - A. Wahab @ A. Rahman, Norasyikin

AU - Zainudin, Suehazlyn

AU - Abaziz, Aini

AU - Mustafa, Norlaila

AU - Sukor, Norlela

AU - Kamaruddin, Nor Azmi

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Adrenal cell carcinoma is a rare tumor and more than 70% of patients present with advanced stages. Adrenal cell carcinoma is an aggressive tumor with a poor prognosis. Surgical intervention is the gold standard treatment and mitotane is the only drug approved for the treatment of adrenal cell carcinoma. Until recently in 2012, the etoposide, doxorubicin, cisplatin plus mitotane are approved as first-line therapy based on response rate and progression-free survival. This case illustrates a case of advanced adrenal cell carcinoma in a young girl who presented with huge adrenal mass with inferior vena cava thrombosis and pulmonary embolism. Multi-approach of therapy was used to control the tumor size and metastasis. Therefore, it may prolong her survival rate for up to 5 years and 4 months.

AB - Adrenal cell carcinoma is a rare tumor and more than 70% of patients present with advanced stages. Adrenal cell carcinoma is an aggressive tumor with a poor prognosis. Surgical intervention is the gold standard treatment and mitotane is the only drug approved for the treatment of adrenal cell carcinoma. Until recently in 2012, the etoposide, doxorubicin, cisplatin plus mitotane are approved as first-line therapy based on response rate and progression-free survival. This case illustrates a case of advanced adrenal cell carcinoma in a young girl who presented with huge adrenal mass with inferior vena cava thrombosis and pulmonary embolism. Multi-approach of therapy was used to control the tumor size and metastasis. Therefore, it may prolong her survival rate for up to 5 years and 4 months.

KW - Advanced adrenal cell carcinoma

KW - Mitotane

KW - Radiofrequency ablation

KW - Sorafenib

KW - Surgical resection

UR - http://www.scopus.com/inward/record.url?scp=84987622040&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84987622040&partnerID=8YFLogxK

M3 - Article

C2 - 27631184

AN - SCOPUS:84987622040

VL - 19

SP - 671

EP - 673

JO - Archives of Iranian Medicine

JF - Archives of Iranian Medicine

SN - 1029-2977

IS - 9

ER -